Multiomics Portrait of the World's Oldest Person Reveals Secrets of Extreme Longevity
Scientists mapped the genome, epigenome, microbiome, metabolome, and proteome of a 117-year-old supercentenarian, uncovering what drives extreme lifespan.
Summary
Researchers performed a comprehensive multiomics analysis of M116, the world's oldest verified living person at 117 years old. By examining her genome, transcriptome, epigenome, metabolome, proteome, and microbiome against matched cohorts, the team identified a dual molecular signature: hallmarks of extreme aging including telomere shortening, clonal hematopoiesis, and abnormal B cell populations coexisted with protective features such as rare resilience-associated genetic variants, low systemic inflammation, a gut bacteriome resembling younger individuals, and an epigenetic clock reading younger than her chronological age. The findings suggest that exceptional longevity is not simply the absence of aging, but rather a balance between aging processes and biological resilience mechanisms.
Detailed Summary
Understanding why some individuals live far beyond average life expectancy while maintaining relatively good health is one of biology's most compelling questions. Supercentenarians — people who survive past 110 — offer a rare natural experiment. M116, a Caucasian woman born in 1907 who held the title of world's oldest verified living person from January 2023 until her death in August 2024 at age 117 years and 168 days, provided a unique opportunity for deep biological investigation.
The research team conducted an unprecedented high-throughput multiomics study, interrogating M116's blood-derived samples across six molecular layers: whole-genome sequencing, transcriptomics, DNA methylation-based epigenomics, metabolomics, proteomics, and gut microbiome profiling. Results were systematically compared against larger age-matched and younger control cohorts to distinguish features unique to extreme longevity from those typical of normal aging.
On the aging side of the ledger, M116 showed clear molecular hallmarks consistent with her chronological age. Telomere length was severely shortened, consistent with extreme cellular age. Clonal hematopoiesis of indeterminate potential (CHIP) was detected, reflecting somatic mutations accumulating in blood stem cells over decades. Her immune profile showed an abnormal B cell population distribution, suggesting age-related immune remodeling. These findings confirm that biological aging processes do proceed even in the world's longest-lived individual.
However, several molecular features distinguished M116 from typical elderly individuals and may help explain her exceptional health span. Genetically, she carried rare European-population variants associated with resilience against age-related diseases. Her metabolomic and proteomic profiles revealed low levels of systemic inflammation markers, a feature consistently linked to healthy aging and reduced cardiovascular and neurodegenerative disease risk. Her gut microbiome composition was strikingly similar to that of much younger individuals, with a bacteriome profile suggesting preserved microbial diversity and reduced pro-inflammatory taxa. Most remarkably, multiple epigenetic clock analyses placed her biological age substantially younger than her 117 chronological years, indicating that her epigenome had aged more slowly than expected.
The authors interpret these findings as evidence that extreme longevity involves a dynamic interplay between unavoidable aging processes and a suite of protective biological mechanisms. Rather than escaping aging, M116 appeared to tolerate its molecular consequences while maintaining systems — immune competence, metabolic balance, microbial ecology, and epigenetic regulation — that buffer against age-associated disease. The study proposes several of these features as candidate biomarkers for healthy aging and potential targets for anti-aging interventions, while acknowledging that translating findings from a single individual to population-level strategies will require larger longitudinal cohorts.
Key Findings
- Telomere attrition, clonal hematopoiesis, and abnormal B cell populations confirmed extreme chronological aging at the molecular level.
- Rare European-population genetic variants associated with disease resilience were identified in M116's genome.
- Gut microbiome composition resembled that of much younger individuals, suggesting preserved microbial health.
- Epigenetic clock analyses indicated a biological age significantly younger than her 117 chronological years.
- Low systemic inflammation markers in metabolome and proteome may underlie absence of major age-associated diseases.
Methodology
This is a single-subject case study with multiomics profiling (whole-genome sequencing, transcriptomics, DNA methylation epigenomics, metabolomics, proteomics, and gut microbiome 16S/metagenomic sequencing) performed on blood-derived samples from M116. Results were compared against larger age-matched and younger control cohorts to contextualize findings. The study is observational and cross-sectional by design.
Study Limitations
The study is based on a single individual, making it impossible to statistically distinguish causal longevity factors from coincidental biological features. Cross-sectional design prevents longitudinal tracking of how these molecular signatures evolved over M116's lifespan. The authors explicitly note that extrapolation to the general population requires larger prospective cohort studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.